Fundraising FoxTransposon Therapeutics
San Diego, US · Founded 2019 · Delaware corporation · 2 known investors
Find your way into Transposon Therapeutics
Sign up to see every warm intro you have to Transposon Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Transposon Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Transposon Therapeutics is a biotechnology company developing therapies for neurodegenerative and aging-related diseases, with a pipeline that includes its lead candidate TPN-101 and novel NRTIs targeting conditions such as PSP, ALS/FTD, and Alzheimer's disease.
Founders & leadership
DP
Dennis PodlesakExecutive
LR
Lynne R. RollinsExecutive
EW
Eckard Weber, MDExecutive
Board
Investors · 2
Reported raises · per SEC filings
Form D private placements$59.1M disclosed across 4 rounds · 2020–2024
▶$4.7MraisedJul 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$4.7MraisedJul 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Keith A. KatkinDirector
- Dennis PodlesakExecutive Officer, Director
- Lynne R. RollinsExecutive Officer
- Daniel Hetu, MD, MBADirector
- Eckard Weber, MDExecutive Officer, Director
- Brent AhrensDirector
- Brian Taylor Slingsby, MD, PHD, MPHDirector
- William Harrington, MD, MBADirector
- John PacificoDirector
- Offering amount
- $20M
- Amount sold
- $4.7M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5MraisedJan 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$5MraisedJan 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Lynne R. RollinsExecutive Officer
- William Harrington, MD, MBADirector
- Brent AhrensDirector
- Daniel Hetu, MD, MBADirector
- Eckard Weber, MDExecutive Officer, Director
- Keith A. KatkinDirector
- Brian Taylor Slingsby, MD, PHD, MPHDirector
- John PacificoDirector
- Offering amount
- $20M
- Amount sold
- $5M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$45.2MraisedDec 2020 · 10 investors · PharmaceuticalsRule 506(b)
▶$45.2MraisedDec 2020 · 10 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakExecutive Officer, Director
- Eckard Weber, M.D.Executive Officer, Director
- John PacificoDirector
- Brent AhrensDirector
- Lynne R. RollinsExecutive Officer
- Offering amount
- $45.2M
- Amount sold
- $45.2M
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4.3MraisedMay 2020 · 4 investors · PharmaceuticalsRule 506(b)
▶$4.3MraisedMay 2020 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dennis PodlesakDirector
- Eckard Weber, M.D.Executive Officer, Director
- Brent AhrensDirector
- John PacificoDirector
- Lynne RollinsExecutive Officer
- Offering amount
- $6.5M
- Amount sold
- $4.3M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Transposon Therapeutics.
Frequently asked questions
- What does Transposon Therapeutics do?
- Transposon Therapeutics is a biotechnology company developing therapies for neurodegenerative and aging-related diseases, with a pipeline that includes its lead candidate TPN-101 and novel NRTIs targeting conditions such as PSP, ALS/FTD, and Alzheimer's disease.
- Who are Transposon Therapeutics's investors?
- Transposon Therapeutics's investors include Canaan Partners, Lumira Ventures.
- How much funding has Transposon Therapeutics raised?
- Transposon Therapeutics has disclosed $59.1M raised across 4 rounds.
- Where is Transposon Therapeutics headquartered?
- Transposon Therapeutics is headquartered in San Diego, US.